Biozatix News – Informasi Popular Sains, Teknologi dan Kesehatan

Cervical Cancer IHC Antibodies

Cervical cancers are a relatively rare diagnosed cancer in the United States, with about 0.7% of new cancer cases classified as cervical, contributing approx. 0.7% of cancer deaths yearly. As of 2011, there were approximately 250,000 women living with cervical cancer in the United States. Those with cervical cancer have a 5 year survival rate of 67.9%. Over the last 10 years, both the new cancer case rate and the death rate have dropped 1.2% and 1.3% per year, respectively. Biocare Medical is proud to offer key cervical antibodies that may aid in the identification of their respective proteins by IHC in FFPE tissues.

cervical cancer antibodies panel_Page_1 cervical cancer antibodies panel_Page_2

List of Antibody: Antib0dy  CD20, Antibody AMACR (RM), Antibody Androgen Receptor,  Antibody Arginase-1, antibody c-erB-2 / HER2 , Antibody c-Myc,  antibody Calponin ,  Antibody Catenin 14/Beta-Catenin,  Antibody CD7,  Antibody CDH17,  Antibody Cytokeratin 5, Antibody Cytokeratin 7,  Antibody Cytokeratin HMW,  antibody e-cadherin,  antibody ERG,  Antibody Estrogen Receptor (ER),  Antibody Folate Receptor alpha,  Antibody GCDFP-15,  Antibody Ki-67,  Antibody Mammaglobin,  antibody P40,  antibody p53,  Antibody p63,  Antibody Phospho-Histone H3,  Antibody Progesterone Receptor (PR),  antibody PTEN, Antibody SOX11.

 

 

Cervical Cancer IHC Antibodies